A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the March 7 2013 Nature by Prof Dimmler, Boon, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Androgen therapy for Myocardial disorders: Androgens improve myocardial function and inhibit myocardial infarction via up regulation of their target genes. By increasing the levels of Androgen, or normalizing the levels of Androgen, one may prevent ageing/stress-associated decline in cardiac function. Together, this study suggests that pharmacological formulations encompassing “Androgens or its analogues” may be used to improve cardiac function after myocardial infarction.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, Androgen therapy for Myocardial disorders: Androgens improve myocardial function and inhibit myocardial infarction via up regulation of their target genes, 1/September/2014, 06.44 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com
* Research cooperation
Significance: This study suggests androgens, by increasing the expression of its target genes, it may (1) improve myocardial function; and (2) decrease cardiac ageing . Furthermore, this study suggests, for the first time, Androgens can be used to treat patients suffering from various myocardial disorders, including myocardial infarction.